Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine
- 12 March 2007
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 21 (5) , 643-645
- https://doi.org/10.1097/qad.0b013e328031f42e
Abstract
During pregnancy, the absorption of antiretroviral drugs may not be optimal, therefore a prospective study was conducted to investigate the plasma levels of lopinavir in 26 HIV-infected pregnant women. Plasma lopinavir levels were examined in specimens obtained 12 h post-dose. The lopinavir level was found to be subtherapeutic in four women (15.4%); one patient who discontinued treatment and three (13.6%) with therapeutic levels of lopinavir had detectable HIV viral loads at the time of therapeutic drug monitoring.Keywords
This publication has 7 references indexed in Scilit:
- Marked Intraindividual Variability in Antiretroviral Concentrations May Limit the Utility of Therapeutic Drug MonitoringClinical Infectious Diseases, 2006
- Guidelines for the management of HIV infection in pregnant women and the prevention of mother‐to‐child transmission of HIVHIV Medicine, 2005
- Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non‐nucleoside reverse transcriptase inhibitorBritish Journal of Clinical Pharmacology, 2004
- Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1–Infected Women and Prevention of Perinatal HIV-1 TransmissionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse‐Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1–Infected Protease Inhibitor–Experienced PatientsThe Journal of Infectious Diseases, 2002
- Pharmacokinetics in pregnancyBest Practice & Research Clinical Obstetrics & Gynaecology, 2001
- Human Serum Attenuates the Activity of Protease Inhibitors toward Wild-Type and Mutant Human Immunodeficiency VirusVirology, 1998